EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation,metastasis and poor prognosis.Targeting and inhibiting EZH2 may be an effective therapeutic strategy for colon cancer.3-D...EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation,metastasis and poor prognosis.Targeting and inhibiting EZH2 may be an effective therapeutic strategy for colon cancer.3-Deazaneplanocin A(DZNep),as an EZH2 inhibitor,can suppress cancer cell growth.However,the anti-cancer role of DZNep in colon cancer cells has been rarely studied.In this study,we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis.The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells.展开更多
目的:探讨组蛋白甲基化抑制剂DZNep在小鼠肾脏缺血再灌注损伤模型中对肾脏的早期保护作用。方法:18只C57BL/6小鼠随机分成假手术组(sham组)、缺血再灌注损伤组(IR组)和缺血再灌注+治疗组(IR+DZNep组)。后两组建立缺血再灌注损伤模型,IR+...目的:探讨组蛋白甲基化抑制剂DZNep在小鼠肾脏缺血再灌注损伤模型中对肾脏的早期保护作用。方法:18只C57BL/6小鼠随机分成假手术组(sham组)、缺血再灌注损伤组(IR组)和缺血再灌注+治疗组(IR+DZNep组)。后两组建立缺血再灌注损伤模型,IR+DZNep组双侧腹股沟皮下注射DZNep(1mg/kg)100μL。假手术组游离双侧肾蒂但不阻断。术后36h采集标本,评价肾功能和肾组织病理学损伤;通过脱氧核糖核苷酸末端转移酶介导的缺口末端标记法(TUNEL)检测肾小管上皮细胞凋亡情况;通过检测髓过氧化物酶(MPO)评价炎症细胞的浸润程度;采用实时定量反转录聚合酶链式反应(qRTPCR)检测肾脏组织相关炎症细胞因子水平。结果:肾脏缺血再灌注损伤后36h,与IR组相连,IR+DZNep组小鼠血肌酐和尿素氮水平明显下降(69.17±3.49 vs 103.83±14.62,9.56±1.07 vs 0.75±15.83;P<0.05);病理损伤减轻,肾小管细胞凋亡减少,炎症细胞因子水平降低(P<0.05)。结论:DZNep可以通过抑制细胞凋亡、减轻炎症反应等方式降低小鼠缺血再灌注损伤肾脏的损伤程度,发挥对肾脏的保护作用。展开更多
目的:探讨过表达或沉默果蝇Zeste基因增强子人类同源物2(enhancer of zeste homolog 2,EZH2)基因对食管癌细胞增殖的影响。方法:选用人食管癌细胞株ECA109、TE1、KYSE30、KYSE170作为研究对象,采用实时荧光定量PCR(q PCR)、Western blot...目的:探讨过表达或沉默果蝇Zeste基因增强子人类同源物2(enhancer of zeste homolog 2,EZH2)基因对食管癌细胞增殖的影响。方法:选用人食管癌细胞株ECA109、TE1、KYSE30、KYSE170作为研究对象,采用实时荧光定量PCR(q PCR)、Western blotting法分别检测食管癌细胞EZH2 m RNA和蛋白的表达水平,然后采用q PCR检测过表达和沉默EZH2基因后对4株食管癌细胞EZH2 m RNA的表达变化;CCK-8增殖实验、克隆形成实验检测过表达和沉默EZH2基因及EZH2抑制剂DZNep(3-deazaneplanocin A)处理对食管癌细胞增殖能力和克隆形成率的影响。结果:食管癌ECA109、TE1细胞中EZH2 m RNA和蛋白水平明显高于KYSE30、KYSE170细胞(P<0.05)。食管癌TE1、ECA109细胞转染EZH2-Sh RNA后EZH2表达水平下调(均P<0.05)、细胞增殖能力降低(1.07±0.08 vs1.59±0.09,P<0.05;0.88±0.08 vs 1.05±0.11,P<0.05)、克隆形成数下调[(200.00±11.43)vs(480.00±13.10)个,P<0.05;(88.00±8.16)vs(220.00±14.69)个,P<0.05]。KYSE30、KYSE170细胞转染EZH2过表达质粒后EZH2表达水平升高(均P<0.05)、细胞增殖能力显著增强(1.06±0.07 vs 0.76±0.06,P<0.05;3.36±0.30 vs 1.50±0.08,P<0.05)、克隆形成数显著升高[(45.00±3.27)vs(18.00±1.63)个,P<0.05;(65.00±4.08)vs(23.00±2.45)个,P<0.05];DZNep处理后,ECA109和TE1细胞增殖能力降低(均P<0.05)、克隆形成数下降(均P<0.05)。结论:EZH2基因能有效促进食管癌细胞的增殖和克隆形成能力,为深入研究EZH2作为食管癌治疗的新靶点提供了实验研究基础。展开更多
基金co-sponsored by Sino-Singapore Collaboration Project from the Ministry of Science and Technology (MOST) of China (No.2013DFG32990)National Natural Science Foundation of China (NSFC Nos.81373438 and 31201040)National Mega-Project for Innovative Drugs by MOST (No.2012ZX09301002-001-015)
文摘EZH2 is over-expressed in human colon cancer and is closely associated with tumor proliferation,metastasis and poor prognosis.Targeting and inhibiting EZH2 may be an effective therapeutic strategy for colon cancer.3-Deazaneplanocin A(DZNep),as an EZH2 inhibitor,can suppress cancer cell growth.However,the anti-cancer role of DZNep in colon cancer cells has been rarely studied.In this study,we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116 cells by inducing cellular senescence and apoptosis.The study provides a novel view of anti-cancer mechanisms of DZNep in human colon cancer cells.
基金supported by the National Natural Science Foundation of China(No.81172356)Application of Basic and Advanced Technology Research Project,Science and Technology Commission of Tianjin Municipality,China(No.10JCZDJC18500)
文摘目的:探讨组蛋白甲基化抑制剂DZNep在小鼠肾脏缺血再灌注损伤模型中对肾脏的早期保护作用。方法:18只C57BL/6小鼠随机分成假手术组(sham组)、缺血再灌注损伤组(IR组)和缺血再灌注+治疗组(IR+DZNep组)。后两组建立缺血再灌注损伤模型,IR+DZNep组双侧腹股沟皮下注射DZNep(1mg/kg)100μL。假手术组游离双侧肾蒂但不阻断。术后36h采集标本,评价肾功能和肾组织病理学损伤;通过脱氧核糖核苷酸末端转移酶介导的缺口末端标记法(TUNEL)检测肾小管上皮细胞凋亡情况;通过检测髓过氧化物酶(MPO)评价炎症细胞的浸润程度;采用实时定量反转录聚合酶链式反应(qRTPCR)检测肾脏组织相关炎症细胞因子水平。结果:肾脏缺血再灌注损伤后36h,与IR组相连,IR+DZNep组小鼠血肌酐和尿素氮水平明显下降(69.17±3.49 vs 103.83±14.62,9.56±1.07 vs 0.75±15.83;P<0.05);病理损伤减轻,肾小管细胞凋亡减少,炎症细胞因子水平降低(P<0.05)。结论:DZNep可以通过抑制细胞凋亡、减轻炎症反应等方式降低小鼠缺血再灌注损伤肾脏的损伤程度,发挥对肾脏的保护作用。
文摘目的:探讨过表达或沉默果蝇Zeste基因增强子人类同源物2(enhancer of zeste homolog 2,EZH2)基因对食管癌细胞增殖的影响。方法:选用人食管癌细胞株ECA109、TE1、KYSE30、KYSE170作为研究对象,采用实时荧光定量PCR(q PCR)、Western blotting法分别检测食管癌细胞EZH2 m RNA和蛋白的表达水平,然后采用q PCR检测过表达和沉默EZH2基因后对4株食管癌细胞EZH2 m RNA的表达变化;CCK-8增殖实验、克隆形成实验检测过表达和沉默EZH2基因及EZH2抑制剂DZNep(3-deazaneplanocin A)处理对食管癌细胞增殖能力和克隆形成率的影响。结果:食管癌ECA109、TE1细胞中EZH2 m RNA和蛋白水平明显高于KYSE30、KYSE170细胞(P<0.05)。食管癌TE1、ECA109细胞转染EZH2-Sh RNA后EZH2表达水平下调(均P<0.05)、细胞增殖能力降低(1.07±0.08 vs1.59±0.09,P<0.05;0.88±0.08 vs 1.05±0.11,P<0.05)、克隆形成数下调[(200.00±11.43)vs(480.00±13.10)个,P<0.05;(88.00±8.16)vs(220.00±14.69)个,P<0.05]。KYSE30、KYSE170细胞转染EZH2过表达质粒后EZH2表达水平升高(均P<0.05)、细胞增殖能力显著增强(1.06±0.07 vs 0.76±0.06,P<0.05;3.36±0.30 vs 1.50±0.08,P<0.05)、克隆形成数显著升高[(45.00±3.27)vs(18.00±1.63)个,P<0.05;(65.00±4.08)vs(23.00±2.45)个,P<0.05];DZNep处理后,ECA109和TE1细胞增殖能力降低(均P<0.05)、克隆形成数下降(均P<0.05)。结论:EZH2基因能有效促进食管癌细胞的增殖和克隆形成能力,为深入研究EZH2作为食管癌治疗的新靶点提供了实验研究基础。
